Long-Term Quality of Life in
Patients with Benign Prostatic
Hypertrophy: Preliminary Results
of a Cohort Survey of 7,093
Patients Treated with an Alpha-1 -
Adrenergic Blocker, Alfuzosin

Lukacs, B.; McCarthy, Caitlin; Grange, J.C.

doi:10.1159/000474372

Cited by 53 publications

(22 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the unique question appended to the I-PSS questionnaire [2] provides an insufficient assess ment of quality of life, these data support results obtained by Lukacs et al [12] showing that alfuzosin improves the quality of life of BPH patients assessed using a French validated questionnaire exploring the physical, psycho logical and social dimensions, including the impact of treatment on sexuality.…”

Section: Discussionsupporting

confidence: 75%

“…This symptomatic improvement is associated with an increase in flow rates and a decrease in residual urine. Efficacy is apparent from the first dose [9] and is maintained up to 30 months [10,11], Furthermore, treatment with alfuzosin has been shown to have a beneficial effect on the patient's quality of life [12,13], Recently, a sustained-release (SR) formulation of alfu zosin, given twice daily, has been developed in order to facilitate the patient's compliance and to further improve cardiovascular safety by delaying the peak plasma con centration. The aim of this study was to assess the medium-term efficacy and the tolerance of this new for mulation, administered without dose titration, in patients with uncomplicated symptomatic BPH.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Sustained- Release Alfuzosin 5 mg in Patients with Benign Prostatic Hyperplasia

Buzelin

Roth²,

Geffriaud-Ricouard³

et al. 1997

Eur Urol

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Sustained- Release Alfuzosin 5 mg in Patients with Benign Prostatic Hyperplasia

Buzelin

Roth²,

Geffriaud-Ricouard³

et al. 1997

Eur Urol

View full text Add to dashboard Cite

“…In BPH, several specific instruments have been devel oped to measure QoL [6][7][8][9][10][11]. Analysis of their content revealed that no consensus has emerged on the concepts that should be measured in evaluating the benefits that BPH patients can expect from treatment.…”

Section: Introductionmentioning

confidence: 99%

Relative Importance of Sexuality and Quality of Life in Patients with Prostatic Symptoms

Silva¹,

Marquis²,

Deschaseaux³

et al. 1997

Eur Urol

108

View full text Add to dashboard Cite

“…Alfuzosin is a selective a 1 -adrenoceptor antagonist with con®rmed ef®cacy and good cardiovascular tolerance in the treatment of BPO [10,11,19]. Besides improving LUTS, treatment with alfuzosin improves the quality of life of patients with BPO [21,22,28]. Moreover, the incidence and severity of orthostatic hypotension is lower with an a 1 -blocker administered as a modi®ed-release formulation than as an immediate-release formulation [16].…”

Section: Discussionmentioning

confidence: 99%

The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

et al. 2000

View full text Add to dashboard Cite

The clinical uroselectivity of alfuzosin is not signi®cantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia i.e. <56, 56±65, 66±75 and >75 years. All groups of patients showed a mean IPSS decrease of 11±12 (55.8±65.4% from baseline) at the end of the study, while the QoL decreased by 2±3 points (55.6±63.6% from baseline). There were no relevant effects of age on the ef®cacy of the treatment. Moreover, alfuzosin was well tolerated independently of the age of the patient; 1.2% of the patients enrolled withdrew because of adverse events. The qualitative distribution of vasodilatory/nonvasodilatory adverse events was similar in all age groups. The incidence of asymptomatic orthostatic hypotension was low (0.58%) and not affected by the age of the patients. Conclusion This study con®rms that the clinical uroselectivity of SR-alfuzosin, already described in randomized controlled studies, is not signi®cantly affected in clinical practice by the age of the patients. This is considered particularly relevant to the characteristics of patients with BPH, as they are mostly elderly men.

show abstract

Long-Term Quality of Life in Patients with Benign Prostatic Hypertrophy: Preliminary Results of a Cohort Survey of 7,093 Patients Treated with an Alpha-1 - Adrenergic Blocker, Alfuzosin

Cited by 53 publications

References 1 publication

Efficacy and Safety of Sustained- Release Alfuzosin 5 mg in Patients with Benign Prostatic Hyperplasia

Efficacy and Safety of Sustained- Release Alfuzosin 5 mg in Patients with Benign Prostatic Hyperplasia

Relative Importance of Sexuality and Quality of Life in Patients with Prostatic Symptoms

The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Contact Info

Product

Resources

About